Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program

This quality improvement study compares US Food and Drug Administration accelerated approvals with Canadian health and technology assessment approvals and timelines for malignant hematology and oncology treatments.

Detalles Bibliográficos
Autores principales: Ho, Cheryl, Lim, Howard J., Regier, Dean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358729/
https://www.ncbi.nlm.nih.gov/pubmed/34379128
http://dx.doi.org/10.1001/jamanetworkopen.2021.20301
_version_ 1783737401951125504
author Ho, Cheryl
Lim, Howard J.
Regier, Dean A.
author_facet Ho, Cheryl
Lim, Howard J.
Regier, Dean A.
author_sort Ho, Cheryl
collection PubMed
description This quality improvement study compares US Food and Drug Administration accelerated approvals with Canadian health and technology assessment approvals and timelines for malignant hematology and oncology treatments.
format Online
Article
Text
id pubmed-8358729
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-83587292021-08-12 Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program Ho, Cheryl Lim, Howard J. Regier, Dean A. JAMA Netw Open Research Letter This quality improvement study compares US Food and Drug Administration accelerated approvals with Canadian health and technology assessment approvals and timelines for malignant hematology and oncology treatments. American Medical Association 2021-08-11 /pmc/articles/PMC8358729/ /pubmed/34379128 http://dx.doi.org/10.1001/jamanetworkopen.2021.20301 Text en Copyright 2021 Ho C et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Ho, Cheryl
Lim, Howard J.
Regier, Dean A.
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title_full Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title_fullStr Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title_full_unstemmed Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title_short Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
title_sort canadian regulatory and health technology assessment for malignant hematology and oncology indications compared with the us food and drug administration accelerated approval program
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358729/
https://www.ncbi.nlm.nih.gov/pubmed/34379128
http://dx.doi.org/10.1001/jamanetworkopen.2021.20301
work_keys_str_mv AT hocheryl canadianregulatoryandhealthtechnologyassessmentformalignanthematologyandoncologyindicationscomparedwiththeusfoodanddrugadministrationacceleratedapprovalprogram
AT limhowardj canadianregulatoryandhealthtechnologyassessmentformalignanthematologyandoncologyindicationscomparedwiththeusfoodanddrugadministrationacceleratedapprovalprogram
AT regierdeana canadianregulatoryandhealthtechnologyassessmentformalignanthematologyandoncologyindicationscomparedwiththeusfoodanddrugadministrationacceleratedapprovalprogram

Ejemplares similares